ARK Investment Management 大幅增持 Beam Therapeutics 股份

根据最近向美国证券交易委员会提交的 13F 表格，ARK Investment Management LLC 在第四季度将其持有的 Beam Therapeutics Inc.（纳斯达克股票代码：BEAM - 免费报告）股份增加了 6.9%。该公司在本季度额外购买了 609,998 股后，拥有 9,393,889 股该公司股票。 Beam Therapeutics 约占 ARK Investment Management LLC 投资组合的 1.5%，使其在该股中排名第 21 位。

ARK Investment Management Bolsters Stake in Beam Therapeutics

ARK Investment Management 增持 Beam Therapeutics 股份

ARK Investment Management LLC has significantly increased its position in shares of Beam Therapeutics Inc. (NASDAQ: BEAM), a biotechnology company focused on developing precision genetic medicines. According to the firm's latest Form 13F filing with the Securities and Exchange Commission, ARK purchased an additional 609,998 shares during the fourth quarter of 2022, representing a 6.9% increase in its holdings.

ARK Investment Management LLC 大幅增持了 Beam Therapeutics Inc.（纳斯达克股票代码：BEAM）的股份，Beam Therapeutics Inc. 是一家专注于开发精准基因药物的生物技术公司。根据该公司向美国证券交易委员会提交的最新 13F 表格，ARK 在 2022 年第四季度额外购买了 609,998 股股票，相当于其持股量增加了 6.9%。

After the transaction, ARK owned 9,393,889 shares of Beam Therapeutics, constituting approximately 1.5% of its portfolio and making BEAM its 21st largest position. The firm's stake in the company was valued at $255,702,000 at the end of the quarter.

交易完成后，ARK 持有 Beam Therapeutics 的 9,393,889 股，约占其投资组合的 1.5%，使 BEAM 成为其第 21 位持仓最多的公司。截至本季度末，该公司持有的该公司股份价值为 255,702,000 美元。

Strong Institutional Support for Beam Therapeutics

对光束治疗的强有力的机构支持

Other hedge funds have also expressed confidence in Beam Therapeutics. Point72 Middle East FZE established a new position in the company during the fourth quarter, valued at approximately $35,000. Allworth Financial LP expanded its holdings by 163.7% during the third quarter, now owning 1,105 shares worth $27,000. Canada Pension Plan Investment Board and Penserra Capital Management LLC both purchased new stakes in the company during the first quarter, valued at approximately $86,000 and $97,000, respectively. Captrust Financial Advisors increased its position by 29.9% in the first quarter, owning 1,845 shares valued at $106,000.

其他对冲基金也表达了对 Beam Therapeutics 的信心。 Point72 Middle East FZE 在第四季度在公司设立了一个新职位，价值约为 35,000 美元。 Allworth Financial LP 第三季度持股量增加了 163.7%，目前持有 1,105 股，价值 27,000 美元。加拿大养老金计划投资委员会和 Penserra Capital Management LLC 在第一季度均购买了该公司的新股份，价值分别约为 86,000 美元和 97,000 美元。 Captrust Financial Advisors 第一季度持仓量增加了 29.9%，持有 1,845 股，价值 106,000 美元。

Institutional investors collectively hold a significant 99.68% of Beam Therapeutics' outstanding shares, reflecting the strong institutional support for the company.

机构投资者合计持有Beam Therapeutics 99.68%的流通股，反映出机构对公司的大力支持。

Insider Transactions

内幕交易

Beam Therapeutics has also experienced some insider activity. Insider Christine Bellon sold 1,907 shares on January 3rd at an average price of $26.42 per share, totaling $50,382.94. Following the transaction, she directly owns 80,495 shares of the company's stock, valued at $2,126,677.90.

Beam Therapeutics 也经历了一些内幕活动。内部人士 Christine Bellon 于 1 月 3 日出售了 1,907 股，平均价格为每股 26.42 美元，总计 50,382.94 美元。交易完成后，她直接拥有该公司80,495股股票，价值2,126,677.90美元。

CEO John M. Evans sold 60,000 shares on January 31st at an average price of $25.33 per share, totaling $1,519,800.00. After the sale, he directly owns 1,058,262 shares, valued at $26,805,776.46.

首席执行官 John M. Evans 于 1 月 31 日出售了 60,000 股，平均价格为每股 25.33 美元，总计 1,519,800.00 美元。出售后，他直接拥有1,058,262股，价值26,805,776.46美元。

In addition to these insider sales, insider Christine Bellon sold another 1,907 shares on January 3rd at the same price of $26.42 per share, bringing her total holdings to 80,495 shares worth $2,126,677.90.

除了这些内部人士出售之外，内部人士克里斯蒂娜·贝隆 (Christine Bellon) 于 1 月 3 日以每股 26.42 美元的相同价格另外出售了 1,907 股，使她的总持股量达到 80,495 股，价值 2,126,677.90 美元。

Over the past 90 days, insiders have sold a total of 63,472 shares of Beam Therapeutics stock, valued at $1,618,322. Insiders currently own 4.40% of the company's shares.

在过去 90 天里，内部人士总共出售了 63,472 股 Beam Therapeutics 股票，价值 1,618,322 美元。内部人士目前持有该公司4.40%的股份。

Stock Performance and Financial Results

股票表现和财务业绩

Beam Therapeutics' stock has witnessed fluctuations in recent times. On Thursday, BEAM traded down $0.92 to close at $33.04. The stock has a 12-month low of $16.95 and a 12-month high of $49.50, with an average daily trading volume of 1,378,971 shares.

Beam Therapeutics 的股票近期出现波动。周四，BEAM 下跌 0.92 美元，收于 33.04 美元。该股12个月最低点为16.95美元，12个月最高点为49.50美元，日均交易量为1,378,971股。

The company's financial performance has been promising. On February 27th, Beam Therapeutics announced its fourth-quarter earnings, reporting earnings per share (EPS) of $1.73, exceeding analysts' consensus estimates by $2.42. Revenue for the quarter reached $316.20 million, significantly surpassing analyst expectations of $34.16 million.

该公司的财务业绩一直充满希望。 2 月 27 日，Beam Therapeutics 公布第四季度财报，每股收益 (EPS) 为 1.73 美元，比分析师普遍预期高出 2.42 美元。该季度收入达到 3.162 亿美元，大幅超出分析师预期的 3416 万美元。

For the full year, equities analysts anticipate that Beam Therapeutics will post a loss per share of $5.50.

股票分析师预计 Beam Therapeutics 全年每股亏损 5.50 美元。

Analyst Opinions and Recommendations

分析师意见和建议

Beam Therapeutics has attracted the attention of numerous analysts. Jefferies Financial Group maintained a "hold" rating but lowered its price target from $75.00 to $30.00. Bank of America downgraded the stock from "buy" to "neutral" and set a price objective of $35.00.

Beam Therapeutics 吸引了众多分析师的关注。 Jefferies Financial Group 维持“持有”评级，但将目标价从 75.00 美元下调至 30.00 美元。美国银行将该股评级从“买入”下调至“中性”，并将目标价设定为 35.00 美元。

TheStreet upgraded BEAM from a "d" rating to a "c-" rating. Barclays raised its price target from $26.00 to $42.00 and gave the company an "equal weight" rating. JPMorgan Chase & Co. upgraded the stock from "neutral" to "overweight" and increased its target price from $38.00 to $40.00.

TheStreet 将 BEAM 从“d”评级升级为“c-”评级。巴克莱将目标价从 26.00 美元上调至 42.00 美元，并给予该公司“同等权重”评级。摩根大通将该股评级从“中性”上调至“增持”，并将目标价从 38.00 美元上调至 40.00 美元。

Currently, eight analysts have assigned Beam Therapeutics a "hold" rating, while five have given it a "buy" rating. The consensus target price among analysts is $41.00, suggesting a potential upside for investors.

目前，八位分析师给予 Beam Therapeutics “持有”评级，五位分析师给予其“买入”评级。分析师一致的目标价为 41.00 美元，这表明投资者有潜在的上涨空间。

About Beam Therapeutics

关于光束疗法

Beam Therapeutics is a biotechnology company developing precision genetic medicines for serious diseases. The company's pipeline includes BEAM-101 for sickle cell disease or beta-thalassemia; BEAM-201 for refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301 and BEAM-302 for glycogen storage disease 1a and severe alpha-1 antitrypsin deficiency, respectively.

Beam Therapeutics 是一家生物技术公司，致力于开发针对严重疾病的精准基因药物。该公司的产品线包括治疗镰状细胞病或β地中海贫血的BEAM-101； BEAM-201治疗难治性T细胞急性淋巴细胞白血病/T细胞淋巴母细胞淋巴瘤； BEAM-301 和 BEAM-302 分别用于治疗糖原累积病 1a 和严重 α-1 抗胰蛋白酶缺乏症。